Fusion Antibodies PLC Stmnt re Share Price Movement (3346B)

TIDMFAB

RNS Number : 3346B

Fusion Antibodies PLC

10 February 2022

Fusion Antibodies plc

("Fusion" or the "Company")

Statement re: movement in share price

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, notes the recent movement in the Company's share price and wish to confirm that the Company is not aware of any specific reason for this.

The Board also confirms that the Company remains well capitalised, that current trading for the year ending 31 March 2022 remains in line with expectations and that there have been no material developments since the publication of the Company's interim results for the six months ended 30 September 2021 on 6 December 2021.

Enquiries:

 
 Fusion Antibodies plc                                    www.fusionantibodies.com 
 Richard Jones, Chief Executive Officer                            Via Walbrook PR 
  James Fair, Chief Financial Officer 
 
 Allenby Capital Limited                                  Tel: +44 (0)20 3328 5656 
 James Reeve/Vivek Bhardwaj (Corporate 
  Finance) 
  Tony Quirke (Sales and Corporate Broking) 
 
 Walbrook PR                     Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com 
 Anna Dunphy                                              Mob: +44 (0)7876 741 001 
 Paul McManus                                             Mob: +44 (0)7980 541 893

About Fusion Antibodies plc

Fusion is a Belfast-based Collaborative Research Organisation ("CRO") company, listed on AIM, providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

Fusion provides a broad range of services in antibody generation, development, characterisation, optimisation, and small-scale production. These services include antigen expression, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx(TM) platform and cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.

At every stage, our client's vision is central to how we work in combining the latest technological advances with cutting edge science. In this work our world-class humanization and antibody optimization platforms harness the power of natural somatic hypermutation (SHM) to ensure the best molecule goes to the clinic. Fusion Antibodies' growth strategy is based on enabling Pharma and Biotech companies get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Fusion's use of SHM to create a fully human antibody library to capture the human antibody repertoire will address a continuing market need in antibody discovery,

Fusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $135.4 billion in 2018 and forecast to surpass $300 billion by 2025, a CAGR of 14.26%. As of May 2021, there were 100 approved antibody therapies on the market and more than 570 antibody therapies in clinical development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

SPMBDGDDLSBDGDG

(END) Dow Jones Newswires

February 10, 2022 07:49 ET (12:49 GMT)

Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Mar 2024 to Apr 2024